EP-262 is under clinical development by Escient Pharmaceuticals and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData, Phase II drugs for Chronic Urticaria Or Hives have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EP-262’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EP-262 overview
EP-262 is under development for the treatment of chronic spontaneous urticaria (CSU), chronic inducible urticaria (CindU), atopic dermatitis (AD), neuro immuno inflammation. The drug candidate acts by targeting Mas-related G-protein coupled receptor member 2 (MRGPRX2). It is administered by oral route.
It was under development for the treatment of autoreactive diseases (autoimmune disorder).
Escient Pharmaceuticals overview
Escient Pharmaceuticals is a pharmaceutical and healthcare company. It develops and commercializes drugs targeting G protein-coupled receptors (GPCRs) for unmet medical needs. The company aims to develop therapies for neuro-immuno-inflammatory and autoreactive diseases. In addition, it’s MRGPRX4 and MRGPRX2 for treatment of cholestatic and uremic pruritus. It is funded by Osage University Partners, The Column Group and 5AM Ventures, Sanofi Ventures, Cowen, Perceptive Advisors, Redmile Group and Altitude Life Science Ventures. Escient Pharmaceuticals is headquartered in San Diego, California, the US.
For a complete picture of EP-262’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
